Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease
about
A comparative study between Wuweizi seed and its post-ethanol extraction residue in normal and hypercholesterolemic mice.Effects of resveratrol in experimental and clinical non-alcoholic fatty liver diseaseSupplementation with the extract of schisandrae fructus pulp, seed, or their combination influences the metabolism of lipids and glucose in mice fed with normal and hypercholesterolemic dietPeroxisome proliferator-activated receptor α activation induces hepatic steatosis, suggesting an adverse effectPeriostin promotes liver steatosis and hypertriglyceridemia through downregulation of PPARα.New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease.Identification of novel multitargeted PPARα/γ/δ pan agonists by core hopping of rosiglitazoneEffects of combined dietary supplementation with fenofibrate and Schisandrae Fructus pulp on lipid and glucose levels and liver function in normal and hypercholesterolemic mice.Treatment with a novel oleic-acid-dihydroxyamphetamine conjugation ameliorates non-alcoholic fatty liver disease in obese Zucker ratsModulation Effect of Peroxisome Proliferator-Activated Receptor Agonists on Lipid Droplet Proteins in Liver.Retinoic acid receptor β2 agonists restore glycaemic control in diabetes and reduce steatosis.Safety considerations with fenofibrate/simvastatin combination.Peroxisome proliferator-activated receptors as targets to treat non-alcoholic fatty liver disease.Non-alcoholic Fatty Liver Disease: A Clinical Update.Role of peroxisome proliferator-activated receptor alpha in the expression of hepatic fatty acid oxidation-related genes in chickens.PPARα agonist fenofibrate enhances fatty acid β-oxidation and attenuates polycystic kidney and liver disease in mice.Activation of PPARα by clofibrate sensitizes pancreatic cancer cells to radiation through the Wnt/β-catenin pathway.The PPARα Agonist Fenofibrate Prevents Formation of Protein Aggregates (Mallory-Denk bodies) in a Murine Model of Steatohepatitis-like HepatotoxicityIntracellular lipids are an independent cause of liver injury and chronic kidney disease in non alcoholic fatty liver disease-like context
P2860
Q30387831-327EDB1D-B754-425E-B984-5B8C8E853FB7Q33563877-B7D9A953-41DA-4A55-910E-A6A7AE55BA38Q33614303-D45AA7CB-98CF-4A6E-9C33-6FA5F6986E71Q33753420-A4CA3368-3A71-4E58-B104-59F528BD8E58Q33944254-E2D32C8B-C67D-4A05-A406-9EB368FE68F7Q34398065-00067B2A-8D99-4108-80AA-C0F9E3CAB4D0Q34511474-FF9BCE46-5049-4E9D-8BCE-B626CBBC4CD0Q35115268-B70D8464-8865-4499-9FA2-104B284C87BEQ36175367-775E8C73-270A-4913-AD84-2431B865748CQ36386635-1043163B-0B18-4E83-B743-5DF76C17B50EQ38296029-771DE27C-6C72-4876-AA91-F0E0601492D9Q38541832-97B76A15-3BC3-402A-AAD7-72CB23929DB5Q41457655-889292D7-ABC5-4589-AFFF-1C7067131AAAQ47100244-F9D6310D-9E0D-44EC-8009-9AF02C2A60C1Q47928475-E304E574-CC4E-420C-8D63-C3BF129CD723Q48662036-D3FC6A4F-1469-4314-A7C6-FF028BB1C1C8Q50068821-270FBAAF-F1EB-45F2-A030-755D7E70C80CQ58699539-FBE08A4F-1310-4085-98DB-9936431A2BCFQ58804230-0A9F86EE-50AA-4D91-B6DA-FAD5B9D3D094
P2860
Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Current role of fenofibrate in ...... -alcoholic fatty liver disease
@en
Current role of fenofibrate in ...... alcoholic fatty liver disease.
@nl
type
label
Current role of fenofibrate in ...... -alcoholic fatty liver disease
@en
Current role of fenofibrate in ...... alcoholic fatty liver disease.
@nl
prefLabel
Current role of fenofibrate in ...... -alcoholic fatty liver disease
@en
Current role of fenofibrate in ...... alcoholic fatty liver disease.
@nl
P2860
P356
P1476
Current role of fenofibrate in ...... -alcoholic fatty liver disease
@en
P2093
Anastazia Kei
P2860
P304
P356
10.4254/WJH.V5.I9.470
P577
2013-09-01T00:00:00Z